-
DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2021-06-14 09:18:08DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive
-
DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2021-06-14 09:12:57DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive
-
DELYTACT® Oncolytic Virus G47∆ Approved in Japan for Treatment of Patients with Malignant GliomaDaiichi Sankyo2021-06-11 17:41:55DELYTACT® Oncolytic Virus G47∆ Approved in Japan for Treatment of Patients with Malignant Glioma
-
Valemetostat Data at EHA Shows Promising Durable Tumor Response in Patients with Peripheral T-Cell Lymphoma and Adult T-Cell Leukemia/LymphomaDaiichi Sankyo2021-06-11 09:11:05Valemetostat Data at EHA Shows Promising Durable Tumor Response in Patients with Peripheral T-Cell Lymphoma
-
Patritumab Deruxtecan Data at ASCO Demonstrates Tumor Response Across Multiple Resistance Mechanisms in Patients with Advanced EGFR-Mutated NSCLCDaiichi Sankyo2021-06-04 14:10:11Patritumab Deruxtecan Data at ASCO Demonstrates Tumor Response Across Multiple Resistance Mechanisms in
-
Daiichi Sankyo Advances Science Across Three Lead DXd ADCs with New Data in Multiple Cancers at 2021 ASCO Virtual MeetingDaiichi Sankyo2021-06-04 10:39:54Daiichi Sankyo Advances Science Across Three Lead DXd ADCs with New Data in Multiple Cancers at 2021 ASCO
-
Datopotamab Deruxtecan Late-Breaking Data at ESMO Breast Shows Promising Preliminary Response and Disease Control in Patients with Metastatic Triple Negative Breast CancerDaiichi Sankyo2021-05-07 09:29:00Datopotamab Deruxtecan Late-Breaking Data at ESMO Breast Shows Promising Preliminary Response and Disease
-
New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA® (edoxaban) in people with atrial fibrillationDaiichi Sankyo2021-04-26 09:44:48New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA® (edoxaban) in people with
-
ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCERDaiichi Sankyo2021-04-20 08:41:52ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2
-
Daiichi Sankyo Initiates Phase 2 Trial to Evaluate Pexidartinib in Japanese Patients with TGCTDaiichi Sankyo2021-04-09 09:03:00Daiichi Sankyo Initiates Phase 2 Trial to Evaluate Pexidartinib in Japanese Patients with TGCT
